This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fabbri, A. Articles by Marchesini, G. Search for Related Content PubMed PubMed Citation Articles by Fabbri, A. Articles by Marchesini, G. Social Bookmarking                         What's this?

Overview of Randomized Clinical Trials of Oral Branched-Chain Amino Acid Treatment in Chronic Hepatic Encephalopathy

Istituto di Clinica Medica Generale e Terapia Medica

Nicola Magrini, MD

Dipartimento di Farmacologia, Università di Bologna, Italy

Giampaolo Bianchi, MD

Istituto di Clinica Medica Generale e Terapia Medica

Marco Zoli, MD

Istituto di Clinica Medica Generale e Terapia Medica

Giulio Marchesini, MD

Istituto di Clinica Medica Generale e Terapia Medica

Background: The role of oral branched-chain amino acid supplements in the prevention and treatment of chronic hepatic encephalopathy is not yet established, and conflicting opinions are expressed in authoritative textbooks. We aimed to review and pool the published controlled studies by means of meta-analytical techniques. Methods: A computerized search of published papers identified nine studies, controlled against placebo, energy, alimentary proteins, or casein. Their quality score was calculated according to the protocol of Chalmers. The value of the portal-systemic encephalopathy index was chosen as main outcome, because of lack of more significant clinical outcomes. To cope with differences in trial design and data presentation, individual data were requested to authors. Results: After 18 months, we received the individual data of only two studies, thus precluding any meta-analysis. Two studies, accounting for over 60% of total enrolled patients, were in favor of branched-chain amino acids. Their quality score was much better than that of the remaining seven negative small studies, carrying a significant risk of type II error. Conclusions: Based on the results of the two largest, long-term studies, the use of oral branched-chain amino acids in the prevention and treatment of chronic encephalopathy may only be proposed for patients with advanced cirrhosis, intolerant to alimentary proteins. Large, multicenter, long-term studies, considering more important clinical outcomes, are needed to provide definite answers to an aged question. (journal of Parenteral and Enteral Nutrition 20:159-164, 1996)

Journal of Parenteral and Enteral Nutrition, Vol. 20, No. 2, 159-164 (1996)
DOI: 10.1177/0148607196020002159


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Charlton Branched-Chain Amino Acid Enriched Supplements as Therapy for Liver Disease J. Nutr., January 1, 2006; 136(1): 295S - 298S. [Abstract] [Full Text] [PDF]

				G. Marchesini, R. Marzocchi, M. Noia, and G. Bianchi Branched-Chain Amino Acid Supplementation in Patients with Liver Diseases J. Nutr., June 1, 2005; 135(6): 1596S - 1601S. [Abstract] [Full Text] [PDF]

				M. L. V. H. Greenfield, A. L. Rosenberg, M. O'Reilly, A. M. Shanks, M. J. Sliwinski, and M. D. Nauss The Quality of Randomized Controlled Trials in Major Anesthesiology Journals Anesth. Analg., June 1, 2005; 100(6): 1759 - 1764. [Abstract] [Full Text] [PDF]

				American Society for Parenteral and Enteral Nutrit Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients JPEN J Parenter Enteral Nutr, January 1, 2002; 26(1_suppl): 1SA - 138SA. [PDF]

				S. M. Riordan and R. Williams Treatment of Hepatic Encephalopathy N. Engl. J. Med., August 14, 1997; 337(7): 473 - 479. [Full Text] [PDF]